OpGen, Inc.

177 articles with OpGen, Inc.

• OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth

  3/1/2023

  OpGen, Inc. and its subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance, announced completion of its move from the incubator space at the Vienna Bio Center into a brand new and tailored state of the art facility at the Abundance Gate in Vienna, Austria.

• OpGen Announces Exercise of All Prefunded Warrants

  2/17/2023

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that all of the prefunded warrants that were issued in its public offering that closed on January 11, 2023 have been exercised in full.

• OpGen subsidiary Ares Genetics announces granting of key patent in China

  1/26/2023

  OpGen, Inc. and OpGen subsidiary, Ares Genetics (Ares) announced today the granting of a key patent by the China National Intellectual Property Administration (CNIPA).

• OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update

  1/18/2023

  OpGen, Inc. today announced preliminary unaudited revenue for 2022.

• OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project

  1/17/2023

  OpGen, Inc. today announced that the Company has received confirmation from FIND, the global alliance for diagnostics, that several key milestones under its collaboration agreement with the global non-profit organization have been successfully met as of the end of 2022.

• OpGen Announces Closing of $7.5 Million Public Offering

  1/11/2023

  OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced public offering of an aggregate of 2,586,207 shares of its common stock (or pre-funded warrants in lieu thereof).

• OpGen Announces Pricing of $7.5 Million Public Offering

  1/7/2023

  OpGen, Inc. announced the pricing of a public offering of an aggregate of 2,586,207 shares of its common stock, Series A-1 warrants to purchase up to 2,586,207 shares of common stock and Series A-2 warrants to purchase 2,586,207 shares of common stock, at a combined public offering price of $2.90 per share and accompanying warrants.

• OpGen Announced 1-for-20 Reverse Stock Split

  1/4/2023

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that the Company’s board of directors has approved a 1-for-20 reverse stock split of its shares of common stock.

• OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

  12/13/2022

  OpGen, Inc. today announced top line data from its successfully completed Unyvero UTI clinical trial. OpGen’s Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens.

• OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results.

• OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time

  10/27/2022

  OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022.

• OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update

  10/27/2022

  OpGen, Inc. announced today that total preliminary unaudited revenue for the third quarter of 2022 was approximately $0.4 million, down from $1.2 million in the third quarter of 2021.

• OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

  10/25/2022

  OpGen, Inc. and BioVersys AG today announced the signing of a collaboration agreement for the deployment and use of the Unyvero platform in BioVersys’ upcoming Phase II clinical trial of novel drug candidate BV100.

• OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

  10/3/2022

  OpGen, Inc. today announced its successful completion of patient enrollment for its clinical trial for the Unyvero Urinary Tract Infection (UTI) Panel.

• OpGen Announces Closing of $3.38 Million Registered Direct Offering

  10/3/2022

  OpGen, Inc. announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 9,660,000 shares of the Company’s common stock, 33,810 shares of Series C mirroring preferred stock and, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 9,660,000 shares of common stock, at a purchase price of $0.35 per share of common stock.

• OpGen Announces $3.38 Million Registered Direct Offering

  9/30/2022

  OpGen, Inc. today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale in a registered direct offering of 9,660,000 shares of the Company’s common stock (or common stock equivalents), 33,810 shares.

• OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform

  9/20/2022

  OpGen, Inc. announced the signing of an R&D collaboration agreement with FIND, the global alliance for diagnostics, for the Unyvero A30 RQ platform for use in rapid pathogen ID and AMR testing from blood culture samples in low and middle income countries.

• OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  OpGen, Inc., announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.

• Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

  8/31/2022

  OpGen, Inc. announced that it has received written notification from the Listing Qualification Department of The NASDAQ Stock Market granting OpGen’s request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550.

• OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory

  8/25/2022

  OpGen, Inc announced today that it has launched next generation sequencing (NGS) services in the U.S. that were developed by its subsidiary, Ares Genetics (“Ares”), which strives to become a leader in bacterial genomics and artificial intelligence (AI)-powered antimicrobial resistance (AMR) solutions.